- KIR3DL1 and HLA-B subtype combinations (strong-, weak-, or non- inhibiting) predict risk of relapse with weak or noninhibiting pairs associated with superior incidence of relapse and OM- Donors with combined weak or noninhibiting subtypes of KIR3DL1/HLA-B and KIR2DS1/HLA-C1 had the lowest relapse rates. This evidence concerns the gene HLA-B and ocular melanoma.